The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

Immunotherapy and particularly immune checkpoint inhibitors have resulted in remarkable clinical responses in patients with immunogenic tumors, although most cancers develop resistance to immunotherapy. The molecular mechanisms of tumor resistance to immunotherapy remain poorly understood. We now sh...

Full description

Bibliographic Details
Main Authors: Daniel Zingg, Natalia Arenas-Ramirez, Dilara Sahin, Rodney A. Rosalia, Ana T. Antunes, Jessica Haeusel, Lukas Sommer, Onur Boyman
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:Cell Reports
Subjects:
immunotherapy
IL-2 complexes
anti-CTLA-4
anti-PD-1
tumor resistance
tumor immune escape
melanoma
epigenetics
EZH2
PRC2
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124717309464

Internet

http://www.sciencedirect.com/science/article/pii/S2211124717309464

Similar Items